Back to results
US 2017/0247443 A1Published application
Safety and Efficacy with a CHO Cell Glycosylated Chimeric Antibody to TNF
AssigneeSorrento Therapeutics, Inc.
InventorsJian Cao, Jeffrey Su
Life of this patent
Estimating the term…
Abstract
There is disclosed a chimeric infliximab-like monoclonal antibody having at least 80% NANA glycosylation terminal sialic acid and a glycosylation pattern of Gal-α(2,3/6)-Gal that binds to tumor necrosis factor alpha (TNF). The disclosed infliximab-like monoclonal antibody is a chimeric antibody having the same amino acid sequence (light chain/heavy chain of SEQ ID NO. 1/SEQ ID NO. 2) as infliximab (Remicade®) which has at least 80% NGNA terminal sialic acid and a glycosylation pattern of Gal-α(1,3)-Gal.
Claims3
A pharmaceutical composition comprising an anti-TNF antibody,
- wherein the anti-TNF antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO:
- 1 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:
- 2, and
- wherein the anti-TNF antibody comprises a glycosylation pattern having at least 80% NGNA terminal sialic acid and a glycosylation pattern of Gal-α(1,3)-Gal n.
1 more element
Dependencies are inferred from the claim text.